Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 1/20 | 0.72 |
| ▸ | TPMT | P51580 | 6/20 | 0.68 |
| ▸ | CA12 | O43570 | 3/20 | 0.66 |
| ▸ | CA1 | P00915 | 3/20 | 0.66 |
| ▸ | CA2 | P00918 | 3/20 | 0.66 |
| ▸ | CA4 | P22748 | 3/20 | 0.66 |
| ▸ | CA6 | P23280 | 3/20 | 0.66 |
| ▸ | CA7 | P43166 | 3/20 | 0.66 |
| ▸ | CA9 | Q16790 | 3/20 | 0.66 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.66 |
| ▸ | CA3 | P07451 | 2/20 | 0.66 |
| ▸ | CA5A | P35218 | 2/20 | 0.66 |
| ▸ | CA5B | Q9Y2D0 | 2/20 | 0.66 |
| ▸ | PKM | P14618 | 1/20 | 0.66 |
| ▸ | HTT | P42858 | 1/20 | 0.59 |
| ▸ | CNR2 | P34972 | 1/20 | 0.54 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | POLA1 | P09884 | 1/20 | 0.49 |
| ▸ | ANTXR2 | P58335 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL668540 | 0.88 | CA12 (0.69) | PTGS2TPMTCA12CA1CA2 | |
| SCHEMBL30615314 | 0.84 | PTGS2 (1.00) | PTGS2TPMTCA12CA1CA2 | |
| SCHEMBL975675 | 0.84 | PTGS2 (1.00) | PTGS2TPMTCA12CA1CA2 | |
| SCHEMBL6066809 | 0.83 | CNR2 (0.62) | PTGS2TPMTCA12CA1CA2 | |
| SCHEMBL16260620 | 0.82 | CA12 (0.62) | PTGS2TPMTCA12CA1CA2 | |
| SCHEMBL1919748 | 0.81 | CA12 (0.64) | PTGS2TPMTCA12CA1CA2 | |
| SCHEMBL503998 | 0.81 | TPMT (1.00) | PTGS2TPMTCA12CA1CA2 | |
| SCHEMBL30240911 | 0.81 | TPMT (1.00) | PTGS2TPMTCA12CA1CA2 | |
| Syringic Acid SCHEMBL6072775 | 0.81 | PTGS2 (0.92) | PTGS2TPMTCA12CA1CA2 | |
| Syringic Acid SCHEMBL27602358 | 0.79 | CA12 (1.00) | PTGS2TPMTCA12CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8129411-B2 | Organic compounds | NOVARTIS AG (CH) | 2012-03-06 | — | — | US | disclosed |
| EP-2420491-A1 | 3 , 5-substitued piperidine compounds as renin inhibitors | Novartis AG (CH) | 2012-02-22 | — | — | EP | disclosed |
| US-20090192148-A1 | Organic Compounds | NOVARTIS AG (CH) | 2009-07-30 | — | — | US | disclosed |
| EP-1968940-A1 | 3 , 5-SUBSTITUED PIPERIDINE COMPOUNDS AS RENIN INHIBITORS | Novartis AG (CH) | 2008-09-17 | — | — | EP | disclosed |
| WO-2007077005-A1 | 3 , 5-SUBSTITΓUED PIPERIDINE COMPOUNDS AS RENIN INHIBITORS | NOVARTIS AG (CH) | 2007-07-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090192148-A1 | Organic Compounds | REN, ACE, AGTR1 | PTGS2 252/4885TPMT 877/4885CA12 2906/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.